Abstract
Collectively, cancers of the gastrointestinal (GI) tract (including the esophagus, stomach, duodenum, colon, rectum, liver, gall bladder and bile ducts) are the most prevalent and deadly worldwide. A common denominator in the pathogenesis of these GI tract cancers is chronic inflammation, as evidenced by the fact that sufferers of inflammatory bowel disease (IBD) are significantly more susceptible to colon cancer than healthy individuals. However, since only a relatively small proportion of individuals with chronic inflammatory conditions such as IBD go on to develop cancer, research has focused on identifying discrepancies in the host immune system that may be responsible for promoting carcinogenesis in inflamed tissue. To this end, molecular pathways linking inflammation and cancer are emerging, with one series of candidates being members of the Toll-like receptor family.
Keywords: Barrett’s esophagus, Cox-2, gastrointestinal cancer, Helicobacter pylori, inflammatory bowel disease, intestinal homeostasis, tolllike receptors, tumor cell proliferation, tumor cell apoptosis.
Current Pharmaceutical Design
Title:Inflammatory and Non-Inflammatory Roles for Toll-Like Receptors in Gastrointestinal Cancer
Volume: 21 Issue: 21
Author(s): Alison C. West and Brendan J. Jenkins
Affiliation:
Keywords: Barrett’s esophagus, Cox-2, gastrointestinal cancer, Helicobacter pylori, inflammatory bowel disease, intestinal homeostasis, tolllike receptors, tumor cell proliferation, tumor cell apoptosis.
Abstract: Collectively, cancers of the gastrointestinal (GI) tract (including the esophagus, stomach, duodenum, colon, rectum, liver, gall bladder and bile ducts) are the most prevalent and deadly worldwide. A common denominator in the pathogenesis of these GI tract cancers is chronic inflammation, as evidenced by the fact that sufferers of inflammatory bowel disease (IBD) are significantly more susceptible to colon cancer than healthy individuals. However, since only a relatively small proportion of individuals with chronic inflammatory conditions such as IBD go on to develop cancer, research has focused on identifying discrepancies in the host immune system that may be responsible for promoting carcinogenesis in inflamed tissue. To this end, molecular pathways linking inflammation and cancer are emerging, with one series of candidates being members of the Toll-like receptor family.
Export Options
About this article
Cite this article as:
West C. Alison and Jenkins J. Brendan, Inflammatory and Non-Inflammatory Roles for Toll-Like Receptors in Gastrointestinal Cancer, Current Pharmaceutical Design 2015; 21 (21) . https://dx.doi.org/10.2174/1381612821666150514104411
DOI https://dx.doi.org/10.2174/1381612821666150514104411 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy The Use of Computational Methods in the Discovery and Design of Kinase Inhibitors
Current Pharmaceutical Design Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Alternative Splicing and Tumor Progression
Current Genomics Patent Selections
Recent Patents on Nanotechnology Antidiabetic Potential of Fabaceae Family: An Overview
Current Nutrition & Food Science Heparan Sulfate Proteoglycans, Tumour Progression and the Cancer Stem Cell Niche
Current Cancer Therapy Reviews Therapeutic Application of Melatonin in the Treatment of Melanoma: A Review
Current Cancer Therapy Reviews Targeting Poly (ADP) Ribose Polymerase I (PARP-1) and PARP-1 Interacting Proteins for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Targeting the Hippo Pathway for Anti-cancer Therapies
Current Medicinal Chemistry Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design The Role of Malnutrition in Older Persons with Mobility Limitations
Current Pharmaceutical Design Nano Carriers Based Approaches for Bioavailability Enhancement of Ora l Hypoglycaemic Agents
Drug Delivery Letters Genomics Can Advance The Potential For Probiotic Cultures To Improve Liver And Overall Health
Current Pharmaceutical Design Electrochemical Study of Ceftazidime-Copper (II) Complex: Synthesis, Characterization, Biological Activity and Analytical Application to Pharmaceutical Dosage Forms
Current Analytical Chemistry Lentinus edodes: A Macrofungus with Pharmacological Activities
Current Medicinal Chemistry Stem Cells, Cancer, Liver, and Liver Cancer Stem Cells: Finding a Way Out of the Labyrinth...
Current Cancer Drug Targets